Non-exclusive Drug Discount Agreement for Beclometasone/Formoterol
Original notice title
Germany – Pharmaceutical products – Abschl. nicht exkl. AM-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines OH-Mod. zum Wirkstoff Beclometason/Formoterol (ATC-Code nach WHO: R03AK08), ausgen. der Wirkst.100µg/6µg als Dosieraerosol
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No guaranteed minimum quantities; actual demand depends on prescription behavior and patient numbers, making revenue un...
The buyer may end the Open-House procedure early if exclusive agreements are signed, typically 8-12 months after public...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- AOK PLUS - Die Gesundheitskasse für Sachsen und Thürigen
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Nov 30, 2026
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until Nov 2026
- Conclusion of non-exclusive drug discount agreements under §130a(8) SGB V for Beclometasone/Formoterol (ATC R03AK08) excluding 100µg/6µg aerosol.
- Open-House model: any eligible pharmaceutical company can participate and accept the terms.
Show full summary
Non-exclusive drug discount agreement (Open-House model) for Beclometasone/Formoterol (ATC R03AK08) excluding the 100µg/6µg aerosol dosage form. The agreement is open to all interested pharmaceutical companies meeting eligibility criteria. No guaranteed minimum volumes, no exclusivity, and the agreement terminates by 30.11.2026. The buyer is AOK PLUS for the regions of Saxony and Thuringia. Estimated value is not disclosed.
Risks
No guaranteed minimum quantities; actual demand depends on prescription behavior and patient numbers, making revenue un...
The buyer may end the Open-House procedure early if exclusive agreements are signed, typically 8-12 months after public...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Participant must be a pharmaceutical enterprise as defined in §4(18) AMG.
Eligibility
- No exclusion grounds under §§123, 124 GWB; must submit self-declaration.
Administrative
- Compliance with EU sanctions against Russia (Regulation 833/2014); must submit self-declaration.
Requirements may be incomplete.
Buyer
Location
Dresden, DEU
Website
Buyer profile
Identifier
DE256878834
Activity
Health
Lots (1)
LOT-0001
Non-exclusive Drug Discount Agreement for Beclometasone/Formoterol
Non-exclusive discount agreement for pharmaceutical products containing Beclometasone/Formoterol (ATC R03AK08), excluding the 100µg/6µg dosage as an aerosol. Open-House model with no guaranteed volumes.
Location
Duration
Category
Deadline
Award details
Siehe Kurzbeschreibung
Value note
Show original TED data
Original lot title
Abschl. nicht exkl. AM-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines OH-Mod. zum Wirkstoff Beclometason/Formoterol (ATC-Code nach WHO: R03AK08), ausgen. der Wirkst.100µg/6µg als Dosieraerosol
Original TED description
Siehe Kurzbeschreibung
Procurement Details
- Publication date
- 17 Sep 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 610285-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
40 / 100
Complexity
20 / 100
Risk factors
No guaranteed minimum quantities; actual demand depends on prescription behavior and patient numbers, making revenue un...
The buyer may end the Open-House procedure early if exclusive agreements are signed, typically 8-12 months after public...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications